KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Return on Capital Employed (2016 - 2025)

Acadia Pharmaceuticals has reported Return on Capital Employed over the past 15 years, most recently at 0.03% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 0.03% for Q4 2025, down 31.0% from a year ago — trailing twelve months through Dec 2025 was 0.03% (down 31.0% YoY), and the annual figure for FY2025 was 0.03%, down 38.0%.
  • Return on Capital Employed for Q4 2025 was 0.03% at Acadia Pharmaceuticals, down from 0.26% in the prior quarter.
  • Over the last five years, Return on Capital Employed for ACAD hit a ceiling of 0.34% in Q4 2024 and a floor of 0.18% in Q3 2022.
  • Median Return on Capital Employed over the past 5 years was 0.03% (2023), compared with a mean of 0.04%.
  • Biggest five-year swings in Return on Capital Employed: soared 50bps in 2024 and later tumbled -31bps in 2025.
  • Acadia Pharmaceuticals' Return on Capital Employed stood at 0.06% in 2021, then plummeted by -66bps to 0.1% in 2022, then plummeted by -76bps to 0.17% in 2023, then surged by 300bps to 0.34% in 2024, then tumbled by -93bps to 0.03% in 2025.
  • The last three reported values for Return on Capital Employed were 0.03% (Q4 2025), 0.26% (Q3 2025), and 0.28% (Q2 2025) per Business Quant data.